ABSORICA in Patients With Severe Recalcitrant Nodular Acne

Completed · Phase 4

Conditions studied: Acne

In brief

This is an uncontrolled, open-label study being conducted in approximately 200 healthy males, non-pregnant, non-nursing females, age 12 to 45 years, with severe recalcitrant nodular acne. ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day will be administered for 4 weeks followed by 1.0 mg/kg/day for 16 weeks. Female subjects consenting to use two forms of birth control or abstinence are included.

Key facts

Study ID
NCT02457520
Run by
Sun Pharmaceutical Industries Limited
People needed
201
Starts
2015-01-21
Expected to finish
2018-04-01
Last updated by the study team
2021-04-27

Who can join

Age: 12 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.